2-Bromo-LSD (BOL-148; Bromolysergide) is a Dopamine Receptor antagonist that directly affects dopamine neurons in the substantia nigra neostriatum. 2-Bromo-LSD increases the hydroxylation of tyrosine in striatum and antagonizes the decrease of Apomorphine-induced DOPA accumulation. 2-Bromo-LSD also blocks the 5-HT Receptor mediated DOPA formation.

Sut-8701 is a Cholecystokinin analog that effectively slows the degenerative process of Alzheimer's disease by protecting the integrity of cholinergic neurons in the nucleus basalis.

CI-1015 is a potent CCK-B receptor antagonist.

A-70874 is a tyrosine-free tetrapeptide analog of cholecystokinin (30-33) (CCK-4). A-70874 is an agonist that stimulates pancreatic amylase release and a partial agonist that stimulates pancreatic phosphoinositide decomposition. A-70874 has an IC50 of 4.9 nM for the guinea pig pancreatic CCK receptor. Cholecystokinin (CCK) receptors are divided into CCK-A (digestive tract) and CCK-B (brain). A-70874 has an affinity of 1.6 μM for the CCK-B/gastrin receptor.

Rimegepant (sulfate hydrate) is an orally active, selective and competitive calcitonin gene-related peptide (CGRP) receptor antagonist with a Ki of 0.027 nM. Rimegepant (sulfate hydrate) can be used in migraine related research.

Δ9-THCP acetate (Δ9-Tetrahydrocannabiphorol acetate) is structurally similar to known phytocannabinoids.

Δ9-THCBA-A (Δ9-Tetrahydrocannabinolic acid-C4) is structurally similar to known phytocannabinoids.

Δ9-Tetrahydrocannabiorcol is structurally similar to known phytocannabinoids.

Δ8-THCPA-A (Δ8-Tetrahydrocannabiphorolic acid) is structurally similar to known phytocannabinoids.

Δ8-THCP (Δ8-Tetrahydrocannabiphorol; n-Heptyl Δ8-THC) (Compound 1a) is a semisynthetic cannabinoid that serves as an analytical reference standard and exhibits affinity for the CB1 receptor.

Δ8-THC-ethyl (Ethyl-Δ8-Tetrahydrocannabinol) is structurally similar to known phytocannabinoids.

Δ8-THCBA-A (Δ8-Tetrahydrocannabibutolic acid A) is structurally similar to known phytocannabinoids.

Δ8-THCB (∆8-Tetrahydrocannabutol) is a structural analog of phytocannabinoids. Δ8-THCB is also an analog of Δ8-tetrahydrocannabinol.

Δ8-THC methyl ether (compound 3) shows a good docking score (-10.167 kcal/mol) for CB2 receptor. Δ8-THC methyl ether has antinociceptive activity in mice.

Δ8-THC Glucuronide is a phytocannabinoid metabolite.

Δ8-Tetrahydrocannabivarin is a cannabinoid.

Δ8-iso-THC is structurally similar to known phytocannabinoids.

Δ4-Iso-THC (Δ4-Iso-tetrahydrocannabinol) is a cannabidiol derivative with potential cytotoxicity targeting cancer cells.

Δ4(8)-iso-THC (Δ4(8)-Isotetrahydrocannabinol) is structurally similar to known phytocannabinoids.

Surinabant (SR 147778) is an orally active, selective cannabinoid receptor type 1 CB1R antagonist. Surinabant is used in studies of obesity and alcoholism.

Rezosicone is the antagonist for cannabinoid CB1 receptor.

PTI-1 is a synthetic cannabinoid (CB) that contains the 1-pentyl-indole structure.

ortho-CBNQ (o-Cannabinolquinone) is an oxidative byproduct of Cannabidiol.

O-2545 hydrochloride is a highly potent, water-soluble CB1/CB2 receptor agonist (with Ki values of 1.5 and 0.32 nM for CB1 and CB2 respectively), can be used for epilepsy, pain, multiple sclerosis research.

NAPIE is structurally similar to known synthetic cannabinoids.

MEP-FUBICA is structurally categorized as a synthetic cannabinoid.

MDMB-FUBICA metabolite 3 is structurally classified as a synthetic cannabinoid. MDMB-FUBICA metabolite 3 is a metabolite of MDMB-FUBICA.

MDMB-FUBICA, a synthetic cannabinoid, is a potent agonist of the cannabinoid receptors with psychoactive properties. MDMB-FUBICA can be used in electronic cigarette.

MDMB-FUB7AICA is structurally similar to known synthetic cannabinoids.

MDA77 is a CB2 inverse agonist with an EC50 of 5.82 nM, showing selectivity for human CB2 and no activity on CB1.